Blood cancers, Low grade lymphoma, Lymphoma, Non-Hodgkin lymphoma (NHL)
Results
Phase 2
This trial looked at lenalidomide for people who had mantle cell non Hodgkin lymphoma. It was for people who had been treated with bortezomib (Velcade).
Doctors often treat mantle cell lymphoma with chemotherapy. If mantle cell lymphoma comes back, doctors are not sure what to treat it with and have few treatments to choose from.
Bortezomib is a type of biological therapy. It is a cancer growth blocker. It stops signals that cancer cells use to divide and grow. Doctors only give bortezomib to people with mantle cell lymphoma as a part of clinical trials.
Lenalidomide is another type of biological therapy. It works mainly by helping the body’s immune system target cancer cells.
The aims of this trial were to find out
If lenalidomide could help people with mantle cell lymphoma after having bortezomib
How safe it was to give lenalidomide to people with mantle cell lymphoma after having bortezomib
Recruitment start: 6 January 2009
Recruitment end: 26 March 2012
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Anton Kruger
Celgene Corporation
Last reviewed: 21 May 2014
CRUK internal database number: 6149
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
Search our clinical trials database for all cancer trials and studies recruiting in the UK.
Connect with other people affected by cancer and share your experiences.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
